Menu

March 2018

Opportunities to Improve Fluoroquinolone Use in Adults Exist in Ambulatory Care Settings

Published March 29, 2018

Systemic fluoroquinolones* (FQ) currently in use include ciprofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin and ofloxacin.   These agents have a number of FDA-approved indications including respiratory tract, genitourinary tract, skin and soft-tissue, intraabdominal, and gastrointestinal tract infections. Because of ongoing safety concerns with FQ use, the FDA issued drug safety communications associated with systemically administered FQ in… Read More

IDSA and SHEA Update Clostridium difficile Infection Clinical Practice Guidelines

Published March 15, 2018

Clostridium difficile* infections (CDI) are associated with significant morbidity and mortality in the United States.  Based on data from 2006 to 2011, studies estimated close to 500,000 CDI cases annually, resulting in 15,000 to 30,000 deaths and 4.8 million dollars in excess costs to acute care facilities.  C difficile infections remain a major public health problem,… Read More

FDA Issues New Safety Communication on Clarithromycin Use in Patients with Heart Disease

Published March 1, 2018

On February 22nd, the Food & Drug Administration (FDA) issued a new drug safety communication to health care providers regarding the long-term risks of clarithromycin use in patients with heart disease.  Clarithromycin is a macrolide antibiotic used for treatment of a variety of respiratory tract and skin infections, and infections caused by Helicobacter pylori and non-tuberculous… Read More

Page last reviewed: November 8, 2018